Pharmaceutical Industry Has Not Made Business Case for Quality
This article was originally published in The Gold Sheet
The pharmaceutical industry has not made the business case for quality, according to a recent PDA survey. A majority of pharmaceutical manufacturers did not calculate the cost of poor quality, yet many have adopted Six Sigma and similar programs for improving quality.
You may also be interested in...
The user fee legislation Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains. The bill directs FDA to inspect based on risk rather than time or location, and to rely on trusted foreign inspectorates, while adding new user fees for generic drugs that will boost funding for further expansion of the agency’s inspectorate.
Proposal could yield a bounty of new options for innovative drug delivery systems.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.